Companies: 10,795·Total market cap: $144.5T
Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc.

INXBNASDAQHealthcare
$15.86
+$1.94(+13.94%)
Market Cap$225865416
P/E Ratio
52W High$18.95
52W Low$12.95

Inhibrx Biosciences, Inc. (INXB) Revenue

Annual & quarterly revenue history · segment & region breakdown

INXB · revenue · updated Jun 9, 2026

Core revenue metrics

Inhibrx Biosciences, Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.00B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
mktCap ÷ TTM rev
Revenue per day
Est. TTM ÷ 365
Revenue / employee
$0K
166 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Inhibrx Biosciences, Inc. SEC filings · GAAPUpdated: 2026-06-09

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
INXB revenue by year · INXB revenue history · INXB annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Inhibrx Biosciences, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Inhibrx Biosciences, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Inhibrx Biosciences, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

INXB revenue · 4 questions

INXB's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.

INXB revenueINXB annual revenuewhat is INXB revenueINXB TTM revenue

Source: FMP · Inhibrx Biosciences, Inc. SEC filings · GAAP · Inhibrx Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026